Press release content from Business Wire. The AP news staff was not involved in its creation.
AbCellera-Discovered Bamlanivimab Together with Etesevimab Reduced Hospitalizations and Prevented Death in Phase 3 Trial for Early COVID-19
March 10, 2021 GMT
VANCOUVER, British Columbia--(BUSINESS WIRE)--Mar 10, 2021--
AbCellera (Nasdaq: ABCL) today announced that bamlanivimab (LY-CoV555) 700 mg, a human antibody discovered by AbCellera and developed with Eli Lilly and Company (Lilly), and etesevimab 1400 mg (LY-CoV16) together reduced COVID-19-related hospitalizations and deaths by 87% in high-risk patients recently diagnosed with COVID-19. These results mark the second positive Phase 3 trial readout for bamlanivimab and etesevimab together, adding to the growing safety and efficacy data that has resulted in the following key milestones accelerating the adoption of the antibody therapy globally: